Cd19: A multifunctional immunological target molecule and its implications for Blineage acute lymphoblastic leukemia

Judith Weiland; Alex Elder; Victoria Forster; Olaf Heidenreich; Steffen Koschmieder; Josef Vormoor

doi:10.1002/pbc.25462

Cd19: A multifunctional immunological target molecule and its implications for Blineage acute lymphoblastic leukemia

Judith Weiland
, Alex Elder
, Victoria Forster
, Olaf Heidenreich
, Steffen Koschmieder
, Josef Vormoor

Research output: Contribution to journal › Review article › peer-review

Abstract

Over the last 20-30 years CD19 has gained attention as a potential target in the therapy of B-cell malignancies. In particular, targeting CD19 with the bispecific T-cell engager (BiTE) antibody Blinatumomab and T-cells modified by chimeric antigen receptors (CAR) has shown promising efficacy in early phase clinical trials for adults and children with precursor B-cell ALL (BCP-ALL). This review will discuss the rationale behind targeting CD19 in BCP-ALL and its potential importance in BCP-ALL signaling pathways.

Original language	English
Pages (from-to)	1144-8
Number of pages	5
Journal	Pediatric Blood & Cancer
Volume	62
Issue number	7
DOIs	https://doi.org/10.1002/pbc.25462
Publication status	Published - Jul 2015
Externally published	Yes

Keywords

Adult
Antibodies, Bispecific/pharmacology
Antigens, CD19/chemistry
Antineoplastic Agents/pharmacology
Clinical Trials as Topic
Humans
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma/drug therapy

Access to Document

10.1002/pbc.25462

Cite this

@article{691eeffcc2a54ce1b7498816d0bde18c,

title = "Cd19: A multifunctional immunological target molecule and its implications for Blineage acute lymphoblastic leukemia",

abstract = "Over the last 20-30 years CD19 has gained attention as a potential target in the therapy of B-cell malignancies. In particular, targeting CD19 with the bispecific T-cell engager (BiTE) antibody Blinatumomab and T-cells modified by chimeric antigen receptors (CAR) has shown promising efficacy in early phase clinical trials for adults and children with precursor B-cell ALL (BCP-ALL). This review will discuss the rationale behind targeting CD19 in BCP-ALL and its potential importance in BCP-ALL signaling pathways.",

keywords = "Adult, Antibodies, Bispecific/pharmacology, Antigens, CD19/chemistry, Antineoplastic Agents/pharmacology, Clinical Trials as Topic, Humans, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma/drug therapy",

author = "Judith Weiland and Alex Elder and Victoria Forster and Olaf Heidenreich and Steffen Koschmieder and Josef Vormoor",

note = "{\textcopyright} 2015 Wiley Periodicals, Inc.",

year = "2015",

month = jul,

doi = "10.1002/pbc.25462",

language = "English",

volume = "62",

pages = "1144--8",

journal = "Pediatric Blood \& Cancer",

issn = "1545-5009",

publisher = "Wiley-Liss Inc.",

number = "7",

}

TY - JOUR

T1 - Cd19

T2 - A multifunctional immunological target molecule and its implications for Blineage acute lymphoblastic leukemia

AU - Weiland, Judith

AU - Elder, Alex

AU - Forster, Victoria

AU - Heidenreich, Olaf

AU - Koschmieder, Steffen

AU - Vormoor, Josef

PY - 2015/7

Y1 - 2015/7

N2 - Over the last 20-30 years CD19 has gained attention as a potential target in the therapy of B-cell malignancies. In particular, targeting CD19 with the bispecific T-cell engager (BiTE) antibody Blinatumomab and T-cells modified by chimeric antigen receptors (CAR) has shown promising efficacy in early phase clinical trials for adults and children with precursor B-cell ALL (BCP-ALL). This review will discuss the rationale behind targeting CD19 in BCP-ALL and its potential importance in BCP-ALL signaling pathways.

AB - Over the last 20-30 years CD19 has gained attention as a potential target in the therapy of B-cell malignancies. In particular, targeting CD19 with the bispecific T-cell engager (BiTE) antibody Blinatumomab and T-cells modified by chimeric antigen receptors (CAR) has shown promising efficacy in early phase clinical trials for adults and children with precursor B-cell ALL (BCP-ALL). This review will discuss the rationale behind targeting CD19 in BCP-ALL and its potential importance in BCP-ALL signaling pathways.

KW - Adult

KW - Antibodies, Bispecific/pharmacology

KW - Antigens, CD19/chemistry

KW - Antineoplastic Agents/pharmacology

KW - Clinical Trials as Topic

KW - Humans

KW - Precursor B-Cell Lymphoblastic Leukemia-Lymphoma/drug therapy

U2 - 10.1002/pbc.25462

DO - 10.1002/pbc.25462

M3 - Review article

C2 - 25755168

SN - 1545-5009

VL - 62

SP - 1144

EP - 1148

JO - Pediatric Blood & Cancer

JF - Pediatric Blood & Cancer

IS - 7

ER -

Cd19: A multifunctional immunological target molecule and its implications for Blineage acute lymphoblastic leukemia

Abstract

Keywords

Access to Document

Fingerprint

Cite this